- Home
- SNCR vs ATOS Comparison
SNCR vs ATOS Comparison
Compare SNCR & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCR
- ATOS
- Stock Information
- Founded
- SNCR 2000
- ATOS 2009
- Country
- SNCR United States
- ATOS United States
- Employees
- SNCR N/A
- ATOS N/A
- Industry
- SNCR EDP Services
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- SNCR Technology
- ATOS Health Care
- Exchange
- SNCR Nasdaq
- ATOS Nasdaq
- Market Cap
- SNCR 101.2M
- ATOS 96.8M
- IPO Year
- SNCR 2006
- ATOS 2012
- Fundamental
- Price
- SNCR $11.44
- ATOS $0.69
- Analyst Decision
- SNCR Strong Buy
- ATOS Strong Buy
- Analyst Count
- SNCR 1
- ATOS 3
- Target Price
- SNCR $13.00
- ATOS $7.00
- AVG Volume (30 Days)
- SNCR 141.8K
- ATOS 527.1K
- Earning Date
- SNCR 05-06-2025
- ATOS 05-12-2025
- Dividend Yield
- SNCR N/A
- ATOS N/A
- EPS Growth
- SNCR N/A
- ATOS N/A
- EPS
- SNCR 0.43
- ATOS N/A
- Revenue
- SNCR $173,594,000.00
- ATOS N/A
- Revenue This Year
- SNCR $5.08
- ATOS N/A
- Revenue Next Year
- SNCR $2.43
- ATOS N/A
- P/E Ratio
- SNCR $25.88
- ATOS N/A
- Revenue Growth
- SNCR 5.72
- ATOS N/A
- 52 Week Low
- SNCR $6.02
- ATOS $0.65
- 52 Week High
- SNCR $15.46
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- SNCR 55.97
- ATOS 41.11
- Support Level
- SNCR $10.55
- ATOS $0.65
- Resistance Level
- SNCR $12.19
- ATOS $0.71
- Average True Range (ATR)
- SNCR 0.78
- ATOS 0.04
- MACD
- SNCR -0.06
- ATOS -0.00
- Stochastic Oscillator
- SNCR 45.56
- ATOS 31.33
About SNCR Synchronoss Technologies Inc.
Synchronoss Technologies Inc is a leading provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and highly scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.